Overview

A Phase III Clinical Study of KW-2246

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.
Treatments:
Citric Acid
Fentanyl